Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05394285
Other study ID # HNCH-MBC10
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 19, 2022
Est. completion date December 28, 2024

Study information

Verified date September 2023
Source Henan Cancer Hospital
Contact min yan
Phone 15713857388
Email ym200678@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study now plans to explore the efficacy and safety of hetrombopag in chemotherapy-induced thrombocytopenia in advanced breast cancer, so as to further guide the clinical application of hetrombopag in chemotherapy-induced platelets.


Description:

Chemotherapy-induced thrombocytopenia increases the risk of hemorrhagic complications, the need for platelet transfusions, and limits the dose of cytotoxic drugs in the treatment of certain malignancies. Thrombopoietin receptor agonist (TPO-RA) has a therapeutic effect on chemotherapy-induced thrombocytopenia (CIT). As an innovative TPO-RA drug, hetrombopag has a more optimized molecular structure and reduced liver and kidney toxicity. A registrational Phase III clinical study in CIT patients is ongoing. This study now plans to explore the efficacy and safety of hetrombopag in chemotherapy-induced thrombocytopenia in advanced breast cancer, so as to further guide the clinical application of hetrombopag in chemotherapy-induced platelets.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 28, 2024
Est. primary completion date December 28, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. The patients signed the informed consent and voluntarily joined the study; 2. Age 18-75 years old, male or female; 3. Patients with advanced breast cancer diagnosed by histopathology or cytology, who are receiving and continue to receive the same chemotherapy regimen; 4. Can accept the current chemotherapy regimen (must be platinum-containing chemotherapy regimen: lobaplatin, carboplatin, cisplatin, etc.) for at least 2 cycles; 5. The first occurrence of platelets <50×109/L in the current chemotherapy cycle; 6. The investigator determines that the patient can receive hetrombopag administration; 7. Neutrophil count = 1.0×109/L, hemoglobin = 80g/L before administration of Haitrombopag; 8. Life expectancy at screening = 12 weeks; 9. ECOG: 0-1; 10. The main organ functions are normal, and there are no serious complications. Exclusion Criteria: 1. Women who are pregnant or breastfeeding; 2. Unable to understand the research nature of the research or have not obtained informed consent; 3. The investigator judges other circumstances that are not suitable for inclusion in the study; 4. Thrombocytopenia caused by other causes (chronic liver disease, sepsis, disseminated intravascular coagulation, immune thrombocytopenia, etc.); 5. Patients with unstable angina pectoris, congestive heart failure, uncontrolled hypertension, uncontrolled arrhythmia or recent history (within 1 year of screening) of myocardial infarction; 6. Those with a history of blood disease or tumor bone marrow infiltration; 7. Those who received simultaneous radiotherapy and those who received pelvic radiotherapy in the past; 8. Arterial or venous thrombotic events within the past 6 months; 9. There are currently uncontrollable infections; 10. Clinical manifestations of severe bleeding within 2 weeks before screening, such as gastrointestinal or central nervous system bleeding; 11. Need emergency treatment, such as superior vena cava syndrome, spinal cord compression; 12. The absolute value of neutrophils is less than 1.0×109/L, and the hemoglobin is less than 80g/L, and granulocyte colony-stimulating factor, red blood cells, and EPO infusion therapy in accordance with clinical routine are allowed; 13. Obvious abnormal liver function: patients without liver metastases, ALT/AST>3ULN (upper limit of normal value), TBIL>3ULN; patients with liver metastases, ALT/AST=5ULN, TBIL=5ULN; 14. Abnormal renal function: serum creatinine = 1.5ULN or eGFR = 60 ml/min (Cockcroft-Gault formula); 16. Received thrombopoietin receptor agonist drugs (such as Eltrombopag, Romigrastim), or recombinant human thrombopoietin (rhTPO), recombinant human interleukin-11 (rhIL) within 1 month before screening -11) Treatment; 17. Received platelet transfusion within 3 days before randomization; 18. Patients with known or expected hypersensitivity or intolerance to the active ingredients or excipients of Hetrombopag ethanolamine tablets.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hetrombopag
The first chemotherapy cycle (single center, open label, randomized controlled): When platelets were <50*109/L, oral hetrombopag 7.5 mg/day was started. When the platelet count is >100*109/L, the administration is suspended. 2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days.
rh-TPO
The first chemotherapy cycle (single center, open label, randomized controlled): Start using rh-TPO 15000 units/day (subcutaneous injection) when platelets are less than 50*109/L. When the platelet count is more than 100*109/L, the administration is suspended. 2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days.

Locations

Country Name City State
China Henan Cancer Hospital Zhengzhou Henan
China Henan Cancer Hospital Zhengzhou

Sponsors (2)

Lead Sponsor Collaborator
Henan Cancer Hospital Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of response rates to platelet-raising therapy in two chemotherapy cycles Definition of response: 1. No chemotherapy regimen adjustment due to thrombocytopenia (such as chemotherapy delay = 5 days, and/or chemotherapy dose reduction = 20%, chemotherapy discontinuation, etc.; 2. No platelet-raising rescue therapy; 3. No Grade 4 myelosuppression; 4. Grade 3 myelosuppression for a duration of = 1 week) 30day±3day after the last administration of Hetrombopag Olamine Tablets
Secondary The lowest platelet value after chemotherapy; The lowest platelet value after chemotherapy; 30day±3day after the last administration of Hetrombopag Olamine Tablets
Secondary The incidence of platelets <50×109/L and <25×109/L; The incidence of platelets <50×109/L and <25×109/L; 30day±3day after the last administration of Hetrombopag Olamine Tablets
Secondary The duration of platelets <50×109/L and <25×109/L; The duration of platelets <50×109/L and <25×109/L; 30day±3day after the last administration of Hetrombopag Olamine Tablets
Secondary The time for platelets to recover to more than 100×109/L; The time for platelets to recover to more than 100×109/L; 30day±3day after the last administration of Hetrombopag Olamine Tablets
Secondary latelet recovery to the highest value after chemotherapy; latelet recovery to the highest value after chemotherapy; 30day±3day after the last administration of Hetrombopag Olamine Tablets
Secondary the incidence of adverse events; the incidence of adverse events; 30day±3day after the last administration of Hetrombopag Olamine Tablets
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A